Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:28:53 ON 09 JUL 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:29:02 ON 09 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9
DICTIONARY FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10549546.str





chain nodes :
7 8 9 10 12 13 14 24
ring nodes :
1 2 3 4 5 6 11 15 16 17 18
chain bonds :
6-7 7-8 7-13 7-14 8-9 8-24 9-10 10-11 10-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-15 11-18 15-16 16-17 17-18
exact/norm bonds :
6-7 7-8 7-13 7-14 8-9 8-24 9-10 10-11 10-12 11-15 11-18 15-16 16-17
17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom
24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:29:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      389 TO ITERATE

100.0% PROCESSED      389 ITERATIONS                          29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          6597 TO     8963
PROJECTED ANSWERS:              257 TO      903

L2            29 SEA SSS SAM L1

=> d scan
```

L2 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[1-oxo-3-[(1-phenylethyl)[[3-(trifluoromethyl)phenyl]sulfony
    l]amino]propyl]-4-(phenylmethyl)- (9CI)
MF C30 H33 F3 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l1 full
FULL SEARCH INITIATED 17:30:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     7220 TO ITERATE

100.0% PROCESSED     7220 ITERATIONS                                 492 ANSWERS
SEARCH TIME: 00.00.01

L3          492 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.55     172.76

FILE 'CAPLUS' ENTERED AT 17:30:11 ON 09 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 9 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 8 Jul 2007  (20070708/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          15 L3

=> d l4 1-15 ibib abs
```

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:259671 CAPLUS
DOCUMENT NUMBER: 146:297694
TITLE: Biocompatible cyanine fluorescent imaging agents and method of in vivo optical imaging
INVENTOR(S): Rajopadhye, Milind; Groves, Kevin
PATENT ASSIGNEE(S): Visen Medical, Inc., USA
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007028163	A1	20070308	WO 2006-US34604	20060901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-714075P P 20050902
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to new fluorescent chemical entities that are designed to attach to biocompatible mols. to form in vivo optical imaging agents. The fluorescence intensity of the fluorophore is enhanced upon attachment to the biocompatible mol. Thus, a fluorophore I was synthesized by reacting the N-hydroxysuccinimidyl ester of corresponding cyanine mol. (1.1mg, 1 μmol) with 3,3-diphenylpropylamine (1.1 mg, 5 μmol) in 115 uL of anhydrous DMF and kept at room temperature for one hour.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:610647 CAPLUS
DOCUMENT NUMBER: 145:224314
TITLE: Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs
AUTHOR(S): Gupta, S. P.; Kumaran, S.
CORPORATE SOURCE: Department of Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India
SOURCE: Medicinal Chemistry (2006), 2(3), 243-250
CODEN: MCEHAJ; ISSN: 1573-4064
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A quant. structure-activity relation study has been conducted on two different series of acyclic hydroxamic acid analogs acting as matrix metalloproteinase (MMP) inhibitors. The results suggest that in a few cases, the hydrophobic property of the mols. is the major governing factor. However, in some cases, the polarizability of the mols. is shown to be dominant. The two enzymes, MMP-9 and MMP-13, are shown to behave in a similar fashion with any group of inhibitors.
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:284145 CAPLUS
DOCUMENT NUMBER: 142:355177
TITLE: Preparation of aminoquinolines for treating inflammatory and immune diseases
INVENTOR(S): Lin, Chu-Chung; Liu, Jen-Fuh; Chang, Chih-Wei; Chen, Shu-Jen; Xiang, Yibin; Cheng, Pei-Chin; Jan, Jiing-Jyh
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 819,646.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005070573	A1	20050331	US 2004-953937	20040929
US 2004209902	A1	20041021	US 2004-819646	20040406
US 7183413	B2	20070227		
AU 2004229404	A1	20041028	AU 2004-229404	20040406
CA 2521619	A1	20041028	CA 2004-2521619	20040406
EP 1613322	A2	20060111	EP 2004-759214	20040406

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2006522814	T	20061005	JP 2006-509778	20040406

PRIORITY APPLN. INFO.:
US 2003-462495P P 20030411
US 2004-551750P P 20040309
US 2004-819646 A2 20040406
WO 2004-US10695 W 20040406

OTHER SOURCE(S): MARPAT 142:355177
GI



I



II

AB The title compds. I [X1-X4 = C; R1, R2 = H, alkyl; or R1 and R2 together

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
are cycloalkyl; R3, R4 = H, AN(B)D; R5-R8 = H, alkyl, or halo; A = alkyl optionally contg. 1-6 heteroatoms; B = H, alkyl; D = alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; or B and D together are heterocycloalkyl or heteroaryl] that bind to CXCR3 receptors and therefore are useful for treating inflammatory and immune diseases, were prepd. E.g., a multi-step synthesis of II, starting from 4,6-dichloro-2-methylquinoline, was given. Ninety exemplified compds. I were tested for their efficacy in blocking activation of CXCR3 using a DELFIA GTP-binding kit (Wallac Oy, Turku, Finland). Unexpectedly, 51 compds. showed IC50 values lower than 1.0 μM, 22 compds. showed IC50 values between 1 μM and 10.0 μM, and 17 compds. showed IC50 values greater than 10.0 μM. The pharmaceutical compn. comprising the compd. I is disclosed.

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:241640 CAPLUS
DOCUMENT NUMBER: 142:463562
TITLE: Synthesis of 3-Arylpiperidines by a Radical 1,4-Aryl Migration
AUTHOR(S): Gheorghe, Alexandru; Quiclet-Sire, Beatrice; Vila, Xavier; Zard, Samir Z.
CORPORATE SOURCE: Laboratoire de Synthese Organique, Departement de Chimie, Ecole Polytechnique, Palaiseau, 91128, Fr.
SOURCE: Organic Letters (2005), 7(8), 1653-1656
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:463562
AB A route to 3-arylpiperidines, 3-arylpyridines, and 5-arylpiperidin-2-ones involving a radical 1,4-aryl migration has been explored. The sequence requires a xanthate addition to an N-allylarylsulfonamide, followed by acetylation and treatment with dilauroyl peroxide to give the 1,4-aryl transfer product, which upon acidic hydrolysis affords the desired piperidine derivative E.g., reaction of 4-MeC6H4SO2NHCH2CH:CH2 and MeO2CCH2SCSOEt gave 4-MeC6H4SO2NHCH2CH(SCSOEt)CH2CH2CO2Me. Acetylation and treatment of the latter with dilauroyl peroxide gave the 1,4-aryl transfer product AcNHCH2CH(C6H4Me-4)CH2CH2CO2Me. 3-Arylpiperidines, 3-arylpyridines, and 5-arylpiperidin-2-ones were prepared from compds. such as AcNHCH2CH(C6H4Me-4)CH2CH2CO2Me.
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:485895 CAPLUS
DOCUMENT NUMBER: 139:223711
TITLE: Novel inhibitors of procollagen C-Proteinase. Part 2: glutamic acid hydroxamates
AUTHOR(S): Robinson, L. A.; Wilson, D. M.; Delaet, N. G. J.; Bradley, E. K.; Dankwardt, S. M.; Campbell, J. A.; Martin, R. L.; Van Wart, H. E.; Walker, K. A. M.; Sullivan, R. W.
CORPORATE SOURCE: CombiChem Inc., San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2381-2384
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:223711
AB Glutamic acid derived hydroxamates were identified as potent and selective inhibitors of procollagen C-proteinase, an essential enzyme for the processing of procollagens to fibrillar collagens. Such compds. have potential therapeutic application in the treatment of fibrosis.
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:699185 CAPLUS
DOCUMENT NUMBER: 133:267150
TITLE: Preparation of amino acid sulfonamide derivatives as inhibitors of aspartyl protease
INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
SOURCE: U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 207,580, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6127372	A	20001003	US 1996-424372	19960401
WO 9524385	A1	19950914	WO 1995-US2420	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1994-207580	B2 19940307
			WO 1995-US2420	W 19950224

OTHER SOURCE(S): MARPAT 133:267150
AB Sulfonamides Z-(CH-D)pC(:G)(CXX')mC(:G')N(D')SO2-E' [Z = N(D), -SO2E, NH-A, N(D)-A, NH-E, NHC(O)N(D)(E), NH-Ht, N(D)-Ht or phthalimidyl (A = Ht or -R1-Ht, where Ht is a heterocycle which may be substituted, R1 = CO, SO2, COCO, O2C, OSO2, NHSO2, NHCO; NHCOCO, which may be substituted); D, D' = aryl, carbocycle, Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl, etc.; m = 1-3; p = 0 or 1; G, G' = H2 or O; X, X' = H, OH, NH2, SH, D, halo or XX' = O] were prepared as aspartyl protease inhibitors. Thus, t-BuNHCON(CH2Ph)CH2CH(OH)N(CH2-cyclopentyl)SO2C6H4OMe-p, prepared by sequential reactions of cyclopentylmethylamine, p-methoxybenzenesulfonyl chloride, epibromohydrin, benzylamine, and t-Bu isocyanate, showed Ki = 2,400 for inhibition of HIV-1 protease.
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:441768 CAPLUS
DOCUMENT NUMBER: 133:74324
TITLE: Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
INVENTOR(S): Billedeau, Roland Joseph; Broka, Chris Allen; Campbell, Jeffrey Allen; Chen, Jian Jeffrey; Dankwardt, Sharon Marie; Delaet, Nancy; Robinson, Leslie Ann; Walker, Keith Adrian Murray
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037436	A1	20000629	WO 1999-EP9920	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355902	A1	20000629	CA 1999-2355902	19991214
BR 9916504	A	20010911	BR 1999-16504	19991214
EP 1149072	A1	20011031	EP 1999-963530	19991214
EP 1149072	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101868	T2	20011121	TR 2001-200101868	19991214
HU 200104658	A2	20020629	HU 2001-4658	19991214
JP 2002533322	T	20021008	JP 2000-589508	19991214
AU 769319	B2	20040122	AU 2000-19792	19991214
NZ 512292	A	20040326	NZ 1999-512292	19991214
AT 270271	T	20040715	AT 1999-963530	19991214
RU 2232751	C2	20040720	RU 2001-119461	19991214
US 6492394	B1	20021210	US 1999-469660	19991222
HR 2001000443	A1	20020630	HR 2001-443	20010614
ZA 2001005014	A	20020919	ZA 2001-5014	20010619
MX 2001PA06328	A	20010910	MX 2001-PA6328	20010620
IN 2001CN00859	A	20050304	IN 2001-CN859	20010620
NO 2001003100	A	20010821	NO 2001-3100	20010621
US 2003199520	A1	20031023	US 2002-267292	20021009
US 6844366	B2	20050118		
US 2003216405	A1	20031120	US 2002-267727	20021009
US 6787559	B2	20040907		
PRIORITY APPLN. INFO.:			US 1998-113311P	P 19981222
			US 1999-147053P	P 19990803
			US 1999-164138P	P 19991108
			WO 1999-EP9920	W 19991214
			US 1999-469660	A3 19991222

OTHER SOURCE(S): MARPAT 133:74324
AB HOHNCOCHR1NRSO2Ar2 [R1 = alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, aminl, aryl, aralkyl, etc.; R = CHR2Ar1, CHR2CH:CHAr1; Ar2 = specified (substituted) Ph, naphthyl; R2 = H, alkyl; with provisos], were prepared Thus, N-hydroxy-2(R)-[(3,4-

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methylenedioxybenzyl)(4-methoxy-2,3,6-trimethylbenzenesulfonyl)amino]-3-methylbutyramide was prepd. by soln. phase synthesis from BOC-D-Val-OH. Title compds. inhibited procollagen C-proteinase with IC50 0.01-2 μM.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:96004 CAPLUS
DOCUMENT NUMBER: 132:151682
TITLE: Preparation of sulfonylaminoalkanediamides and related compounds as matrix metalloproteinase inhibitors.
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK
SOURCE: U.S., 32 pp., Cont.-in-part of Ser. No. Wo97GB-9702891.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6022873	A	20000208	US 1998-121033	19980723
WO 9817655	A1	19980430	WO 1997-GB2891	19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PT 1030842	T	20030731	PT 1997-912351	19971113
ES 2195122	T3	20031201	ES 1997-912351	19971113
PRIORITY APPLN. INFO.:			GB 1996-21814	A 19961019
			WO 1997-GB2891	A2 19971020
			EP 1997-912351	A 19971113

OTHER SOURCE(S): MARPAT 132:151682
AB VCOCH[(CH2)nNR3SO2R4]CHR1COR2 [V = HO, HONH; n = 1-4; R1 = alkyl, alkenyl, alkynyl, perfluoroalkyl, phenylalkyl, heteroarylalkyl, cycloalkylalkyl, etc.; R2 = 5-8 membered (substituted) N-heterocyclyl; R3 = H, alkyl, cycloalkyl, Ac; R4 = (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, etc.; R3R4 = (substituted) alkylene, alkenylene], were prepared Thus, 2S-[(4-methoxybenzenesulfonylamino)ethyl]-5-methyl-3R-(piperidine-1-carbonyl)hexanoic acid hydroxamide [prepared from 2S-(2-hydroxyethyl)-3R-isobutylsuccinic acid 4-benzyl ester 1-tert-Bu ester] inhibited human fibroblast collagenase with IC50 = 50 nM.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:761121 CAPLUS
DOCUMENT NUMBER: 131:351674
TITLE: Preparation of N-(arylsulfonyl)valine hydroxamic acids and analogs as matrix metalloproteinase inhibitors or TNF production inhibitors
INVENTOR(S): Robinson, Ralph P.; Rizzi, James P.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5994351	A	19991130	US 1998-122920	19980727
US 5863949	A	19990126	US 1997-894873	19970804
US 6147074	A	20001114	US 1999-406522	19990928
US 6380219	B1	20020430	US 2000-635186	20000808
PRIORITY APPLN. INFO.:			WO 1995-US2679 W	19950307
			US 1997-894873 A3	19970804
			US 1998-122920 A3	19980727
			US 1999-406522 A3	19990928

OTHER SOURCE(S): MARPAT 131:351674
AB RSO2N[(CH2)nCOX]CR3R4CONHOH [R = (un)substituted (hetero)aryl; R3,R4 = H, OH, alkyl, (hetero)aryl(alkyl), etc.; X = OH, alkoxy, NR1R2; R1,R2 = H, alkyl, (un)substituted piperidyl, etc.; NR1R2 = heterocyclyl] were prepared as matrix metalloproteinase inhibitors or TNF production inhibitors (no data).
Thus, (R)-H2NCH(CHMe2)CO2CH2Ph was amidated by 4-(MeO)C6H4SO2Cl and the product N-alkylated by BrCH2CO2CMe3 to give, after saponification, (R)-4-(MeO)C6H4SO2N(CH2COX)CH(CHMe2)COR5 (I; R5 = OCH2Ph, X = OH) which was converted in 4 addnl. steps to I (R5 = NHOH, X = morpholino).
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:662331 CAPLUS
DOCUMENT NUMBER: 132:30315
TITLE: The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors
AUTHOR(S): Martin, Fionna M.; Beckett, R. Paul; Bellamy, Claire L.; Courtney, Paul F.; Davies, Stephen J.; Drummond, Alan H.; Dodd, Rory; Pratt, Lisa M.; Patel, Sanjay R.; Ricketts, Michelle L.; Todd, Richard S.; Tuffnell, Andrew R.; Ward, John W. S.; Whittaker, Mark
CORPORATE SOURCE: British Biotech Pharmaceuticals Limited, Oxford, OX4 5LY, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(19), 2887-2892
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel sulfonamide matrix metalloproteinase inhibitors most with piperidine amide were synthesized by a route involving a stereoselective conjugate addition reaction. Enzyme selectivity was dependent on the nature of the sulfonamide substituents. Several compds. are potent selective collagenase inhibitors with good oral bioavailability.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:626184 CAPLUS
DOCUMENT NUMBER: 131:242793
TITLE: Preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9948881	A1	19990930	WO 1998-GB914	19980325
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9868435	A	19991018	AU 1998-68435	19980325
EP 1066273	A1	20010110	EP 1998-913910	19980325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003522723	T	20030729	JP 2000-537864	19980325

PRIORITY APPLN. INFO.: WO 1998-GB914 A 19980325
AB Hydroxamic acids and carboxylic acids, e.g. 2S-{[(5-dimethylaminonaphthalene-1-sulfonyl)methylamino]methyl}-5-methyl-3R-(morpholine-4-carbonyl)hexanoic acid hydroxyamide, matrix metalloproteinase inhibitors, were prepared
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:268494 CAPLUS
DOCUMENT NUMBER: 128:308398
TITLE: Preparation of hydroxamides as metalloproteinase inhibitors
INVENTOR(S): Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Ltd., UK; Beckett, Raymond Paul; Martin, Fionna Mitchell; Miller, Andrew; Todd, Richard Simon; Whittaker, Mark
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817655	A1	19980430	WO 1997-GB2891	19971020
W: AU, BR, CA, CN, CZ, DE, GB, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2269283	A1	19980430	CA 1997-2269283	19971020
AU 9747142	A	19980515	AU 1997-47142	19971020
AU 713603	B2	19991209		
GB 2324091	A	19981014	GB 1998-16616	19971020
GB 2324091	B	20001115		
EP 934292	A1	19990811	EP 1997-909461	19971020
EP 934292	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NZ 334711	A	20001027	NZ 1997-334711	19971020
JP 2001502348	T	20010220	JP 1998-519112	19971020
AT 320422	T	20060415	AT 1997-909461	19971020
PT 1030842	T	20030731	PT 1997-912351	19971113
ES 2195122	T3	20031201	ES 1997-912351	19971113
ZA 9710611	A	19980612	ZA 1997-10611	19971125
US 6022873	A	20000208	US 1998-121033	19980723

PRIORITY APPLN. INFO.: GB 1996-21814 A 19961019
WO 1997-GB2891 W 19971020
EP 1997-912351 A 19971113

OTHER SOURCE(S): MARPAT 128:308398
GI



AB The title compds. [I; V = OH, NHOH; n = 1-4; R1 = C1-12 alkyl, C2-12

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
alkenyl, C2-12 alkynyl, etc.; R2 = (un)substituted 5-8 membered monocyclic or bridged N-heterocyclic ring; R3 = H, C1-6 alkyl, benzyl, etc.; R4 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.], which are matrix metalloproteinase inhibitors and therefore are useful in the treatment of rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, or a neuroinflammatory disorder, were prepd. Thus, multi-step synthesis starting from 2S-(2-hydroxyethyl)-3R-isobutyl-succinic acid 4-benzyl ester 1-tert-Bu ester afforded the title compd. (2S,3R)-II which showed IC50 of ca. 50 nM against human fibroblast collagenase.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:147308 CAPLUS
DOCUMENT NUMBER: 128:192672
TITLE: Preparation of arylsulfonylaminohydroxamic acid derivatives as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF)
INVENTOR(S): Blumenkopf, Todd A.; Robinson, Ralph P.
PATENT ASSIGNEE(S): Pfizer Inc., USA; Blumenkopf, Todd A.; Robinson, Ralph P.
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807697	A1	19980226	WO 1997-IB924	19970725
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264284	A1	19980226	CA 1997-2264284	19970725
AU 9734563	A	19980306	AU 1997-34563	19970725
AU 711585	B2	19991014		
EP 922030	A1	19990616	EP 1997-930699	19970725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9711223	A	19990817	BR 1997-11223	19970725
CN 1228083	A	19990908	CN 1997-197354	19970725
JP 2000501423	T	20000208	JP 1998-510535	19970725
TW 397823	B	20000711	TW 1997-86112058	19970820
US 6153609	A	20001128	US 1999-242504	19990216
NO 9900821	A	19990223	NO 1999-821	19990222

PRIORITY APPLN. INFO.: US 1996-24675P P 19960823
WO 1997-IB924 W 19970725

OTHER SOURCE(S): MARPAT 128:192672
AB The title compds. HONHC(O)C(R3)(R4)N(SO2Q)(CH2)nC(O)X [I; n = 1-6; X = OR1; R1 = piperidinyl, piperazinyl, indolinyl, etc.; R3, R4 = H, C1-6 alkyl, CF3, etc.; R3R4 = C3-6 cycloalkyl, oxacyclohexyl, indanyl, etc.; Q = C1-6 alkyl, C6-10 aryl, C5-9 heteroaryl, etc.] and their salts, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF, were prepared In addition, the compds. I may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer. Thus, the 8-step detailed synthesis of compound I [X = 4-[tert-butoxycarbonyl(methyl)amino]piperidin-1-yl; n = 2; Q = 4-(MeO)C6H4; R3 = H; R4 = cyclohexyl] is described. Compds. I are effective at 0.3-5 mg/kg/day.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:632249 CAPLUS
DOCUMENT NUMBER: 125:276574
TITLE: Preparation of (arylsulfonylamino)hydroxamates as matrix metalloproteinase and tumor necrosis factor production inhibitors
INVENTOR(S): Robinson, Ralph P.; Rizzi, James P.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627583	A1	19960912	WO 1996-US2679	19960307
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
IL 117343	A	20020814	IL 1996-117343	19960304
CA 2214720	A1	19960912	CA 1996-2214720	19960307
CA 2214720	C	20040127		
AU 9650293	A	19960923	AU 1996-50293	19960307
AU 707510	B2	19990715		
ZA 9601876	A	19970916	ZA 1996-1876	19960307
EP 813520	A1	19971229	EP 1996-907134	19960307
EP 813520	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
BR 9607362	A	19971230	BR 1996-7362	19960307
CN 1181066	A	19980506	CN 1996-193213	19960307
CN 1122662	B	20031001		
HU 9800462	A2	19980728	HU 1998-462	19960307
JP 11501910	T	19990216	JP 1996-526918	19960307
JP 3753737	B2	20060308		
RU 2145597	C1	20000220	RU 1997-116727	19960307
AT 211131	T	20020115	AT 1996-907134	19960307
PT 813520	T	20020429	PT 1996-907134	19960307
ES 2169794	T3	20020716	ES 1996-907134	19960307
PL 184158	B1	20020930	PL 1996-322131	19960307
CZ 291106	B6	20021211	CZ 1997-2782	19960307
FI 9703613	A	19971105	FI 1997-3613	19970905
NO 9704103	A	19971105	NO 1997-4103	19970905
NO 313752	B1	20021125		
CN 1316419	A	20011010	CN 2001-111743	20010323
PRIORITY APPLN. INFO.:			US 1995-401049 A1	19950308
			WO 1996-US2679 W	19960307
OTHER SOURCE(S):	MARPAT 125:276574			

GI

L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB HONHCOCR3R4N(SO2R)(CH2)nCOX [R = (hetero)aryl; R3,R4 = H, alkyl, CF3, (hetero)aryl, etc.; X = OH, alkoxy, NR1R2; R1,R2 = H, alkyl, piperidiyl, (hetero)aryl, etc.; NR1R2 = heterocyclyl; n = 1-6] were prepared as matrix metalloproteinase and tumor necrosis factor production inhibitors (no data). Thus, D-Me2CHCH(NH2)CO2CH2Ph was successively N-substituted by 4-(MeO)C6H4SO2Cl and BrCH2CO2CMe3 and the sapond. product amidated by morpholine to give, in 3 addnl. steps, title compound (R)-I (R3 = CHMe2).

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:994876 CAPLUS
DOCUMENT NUMBER: 124:116874
TITLE: Preparation of sulfonamide derivatives as aspartyl protease inhibitors
INVENTOR(S): Tung, Roger Dennis; Salituro, Francesco Gerald; Deininger, David D.; Murcko, Mark Andrew; Novak, Perry Michael; Bhisetti, Govinda Rao
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524385	A1	19950914	WO 1995-US2420	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2183653	A1	19950914	CA 1995-2183653	19950224
AU 9519332	A	19950925	AU 1995-19332	19950224
AU 699483	B2	19981203		
EP 749421	A1	19961227	EP 1995-911960	19950224
EP 749421	B1	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1146201	A	19970326	CN 1995-192473	19950224
JP 10500938	T	19980127	JP 1995-523497	19950224
AT 184594	T	19991015	AT 1995-911960	19950224
ES 2139195	T3	20000201	ES 1995-911960	19950224
ZA 9501688	A	19951211	ZA 1995-1688	19950301
IN 1995CA00242	A	20050304	IN 1995-CA242	19950306
US 6127372	A	20001003	US 1996-424372	19960401
HK 1012622	A1	20000922	HK 1998-113972	19981217
GR 3032151	T3	20000427	GR 1999-403237	19991215
PRIORITY APPLN. INFO.:			US 1994-207580 A	19940307
			WO 1995-US2420 W	19950224
OTHER SOURCE(S):	MARPAT 124:116874			

GI



I

AB Z(CHD)pC(:G)(CXX')mC(:G')ND'SO2E' [D,D' = aryl, heterocyclyl, NH2, alkyl, etc.; E,E' = OH, NH2, aryl, heterocyclyl, etc.; G,G' = H2, O; X,X' = H, oh, NH2, halo, etc.; XX' = O; Z = NDSO2E, NHA, NHE, heterocyclyl, etc.; A

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
= H, (cyclo)alkyl, Ph, heterocyclyl, etc.; m = 1-3; p = 0 or 1] were prepd. Title compd. I had Ki of 7nM against HIV-1 protease.

=> d l4 1-15 hitstr

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 928031-23-6P 928031-25-8P 928031-27-0P
928031-31-6P 928031-35-0P
RL: DGN (Diagnostic use); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(production of biocompatible fluorescent imaging agents for in vivo optical
imaging)
RN 928031-23-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-22-5
CMF C63 H73 N5 O15 S5

PAGE 1-A



PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 928031-25-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-24-7
CMF C64 H75 N5 O15 S5

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 928031-31-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-30-5
CMF C62 H70 N4 O16 S5

PAGE 1-A



L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 928031-27-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-26-9
CMF C64 H70 N6 O16 S5

PAGE 1-A



L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 928031-35-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 928031-34-9
CMF C61 H68 N4 O15 S5

PAGE 1-A



PAGE 1-B



L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 121-44-8
CMF C6 H15 N

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 206553-57-3 206553-72-2 244296-01-3
244296-09-1 244296-22-8 244296-25-1
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(QSAR studies of hydroxamic acid analogs on matrix metalloproteinase inhibitors)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[(5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 849110-84-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoquinolines for treating inflammatory and immune diseases)
RN 849110-84-5 CAPLUS
CN Piperidine, 1-[3-[[2-[(6-chloro-2-methyl-4-quinolinyl)amino]ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 851461-08-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and radical 1,4-aryl migration reaction of)
RN 851461-08-0 CAPLUS
CN Carbonodithioic acid, S-[1-[[acetyl[(4-bromophenyl)sulfonyl]amino]methyl]-4-oxo-4-(1-piperidinyl)butyl] O-ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 279254-86-3P 279254-91-0P 279254-97-6P
279255-03-7P 279255-56-0P 279255-58-2P
591766-09-5P 591766-10-8P 591766-11-9P
591766-12-0P 591766-13-1P 591766-14-2P
591766-15-3P 591766-16-4P 591766-17-5P
591766-18-6P 591766-19-7P 591766-20-0P
591766-21-1P 591766-22-2P 591766-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and structure-activity relationship of glutamic acid hydroxamates as novel inhibitors of procollagen C-Proteinase)
RN 279254-86-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-03-7 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 591766-12-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-13-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-14-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-



RN 591766-09-5 CAPLUS
CN 1-Piperidinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-10-8 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-11-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-methyl-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-15-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-16-4 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(3-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-17-5 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(4-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-18-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-19-7 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-20-0 CAPLUS

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 591766-23-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[[(3-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-21-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591766-22-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-4-[[(4-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 172738-38-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid sulfonamide derivs. as inhibitors of aspartyl protease)
RN 172738-38-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-[[(1,1-dimethylethyl)amino]carbonyl]-4-[(3S)-3-hydroxy-4-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-oxobutyl]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 279254-86-3P 279254-88-5P 279254-89-6P
279254-90-9P 279254-91-0P 279254-92-1P
279254-97-6P 279254-98-7P 279255-01-5P
279255-02-6P 279255-03-7P 279255-15-1P
279255-16-2P 279255-21-9P 279255-25-3P
279255-56-0P 279255-58-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase)

RN 279254-86-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-88-5 CAPLUS
CN 1-Piperazinepentanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][(4-methyl-3-nitrophenyl)methyl]amino]-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-89-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-



RN 279254-92-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-97-6 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

methoxyphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-90-9 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[[(3-fluorophenyl)methyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-91-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(4R)-4-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-5-(hydroxyamino)-1,5-dioxopentyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279254-98-7 CAPLUS
CN 1-Piperazinepentanamide, α-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-01-5 CAPLUS
CN 1-Piperazinepentanamide, α-[[(3-fluorophenyl)methyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(2-pyridinyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-02-6 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[[(3-fluorophenyl)methyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-03-7 CAPLUS
CN 1-Piperazinepentanamide, 4-acetyl-α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl]sulfonyl]amino]-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-21-9 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-δ-oxo-4-(phenoxyacetyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-25-3 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-(methylsulfonyl)-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-15-1 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[[(4-methylphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-16-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N-hydroxy-4-[[(3-methoxyphenyl)amino]carbonyl]-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-56-0 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-benzoyl-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 279255-58-2 CAPLUS
CN 1-Piperazinepentanamide, α-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-(2-furanylcarbonyl)-N-hydroxy-δ-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

IT 206553-54-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-64-2P 206553-66-4P
206553-67-5P 206553-68-6P 206553-70-0P
206553-72-2P 206553-74-4P 206553-75-5P
206553-76-6P 206553-77-7P 206553-78-8P
206553-81-3P 244296-01-3P 244296-06-8P
244296-07-9P 244296-09-1P 244296-10-4P
244296-16-0P 244296-17-1P 244296-22-8P
244296-23-9P 244296-25-1P 244296-26-2P
244296-27-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

RN 206553-54-0 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-55-1 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[2-[[(4-methoxyphenyl)sulfonyl]methylamino]ethyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-63-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-64-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-66-4 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chloro-2,5-dimethylphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-67-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(2,5-dimethoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-68-6 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-β-(2-methylpropyl)-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-70-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-74-4 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(2-naphthalenylsulfonyl)amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-75-5 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)



RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl[(4-methylphenyl)sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 206553-76-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[([1,1'-biphenyl]-4-ylsulfonyl)methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[(5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[(5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-23-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-26-2 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[(5-isoquinolinylsulfonyl)methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 244296-17-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-16-0
CMF C28 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-27-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[6-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206553-91-5P 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonylaminoalkanediamides and related compds. as matrix metalloproteinase inhibitors)

RN 206553-91-5 CAPLUS
CN 1-Piperidinebutanoic acid, α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI)

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 182319-61-5P 182319-62-6P 182319-78-4P
182319-79-5P 182319-83-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(arylsulfonyl)valine hydroxamic acids and analogs as matrix metalloproteinase inhibitors or TNF production inhibitors)
RN 182319-61-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-62-6 CAPLUS
CN Butanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperazinyl)propyl]amino]-3-methyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 182319-78-4 CAPLUS
CN Butanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 182319-79-5 CAPLUS
CN Butanamide, N,3-dihydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperidinyl)propyl]amino]-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-83-1 CAPLUS
CN Cyclohexaneacetamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 206553-57-3P 206553-72-2P 244296-01-3P
244296-09-1P 244296-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluation of non-peptidic matrix metalloproteinase inhibitors in relation to oral bioavailability)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-72-2 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 244296-09-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-10-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-09-1
CMF C29 H42 N4 O5 S

Absolute stereochemistry.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

IT 244296-01-3P 244296-06-8P 244296-07-9P
244296-09-1P 244296-10-4P 244296-16-0P
244296-17-1P 244296-22-8P 244296-23-9P
244296-25-1P 244296-26-2P 244296-28-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase
inhibitors)

RN 244296-01-3 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[[(4-methoxyphenyl]sulfonyl]methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-06-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-07-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[ethyl[(4-methoxyphenyl)sulfonyl]amino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-16-0 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-17-1 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]ethylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 1

CRN 244296-16-0
CMF C28 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 244296-22-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-β-(cyclopentylmethyl)-N-hydroxy-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-23-9 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-γ-oxo-, (αR,βR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 244296-27-3
CMF C29 H42 N4 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)
RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-25-1 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[methyl(1-naphthalenylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-26-2 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-N-hydroxy-α-[[(5-isoquinolinylsulfonyl)methylamino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244296-28-4 CAPLUS
CN 1-Piperidinebutanamide, β-(cyclopentylmethyl)-α-[[[[6-

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 206553-57-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxamic acids and carboxylic acids as metalloproteinase inhibitors)
RN 206553-57-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN

IT 206553-54-0P 206553-55-1P 206553-57-3P
206553-63-1P 206553-64-2P 206553-66-4P
206553-67-5P 206553-68-6P 206553-70-0P
206553-72-2P 206553-74-4P 206553-75-5P
206553-76-6P 206553-77-7P 206553-78-8P
206553-81-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamides as metalloproteinase inhibitors)

RN 206553-54-0 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-55-1 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-α-[2-[[(4-methoxyphenyl)sulfonyl]methylamino]ethyl]-β-(2-methylpropyl)-γ-oxo-, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-57-3 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-67-5 CAPLUS

CN 1-Piperidinebutanamide, α-[[[(2,5-dimethoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-68-6 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-β-(2-methylpropyl)-α-[[methyl(8-quinolinylsulfonyl)amino]methyl]-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-70-0 CAPLUS

CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-63-1 CAPLUS

CN 1-Piperidinebutanamide, α-[[[(4-butoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-64-2 CAPLUS

CN 1-Piperidinebutanamide, α-[[[[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-66-4 CAPLUS

CN 1-Piperidinebutanamide, α-[[[(4-chloro-2,5-dimethylphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-72-2 CAPLUS

CN 1-Piperidinebutanamide, α-[[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-74-4 CAPLUS

CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl(2-naphthalenylsulfonyl)amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-75-5 CAPLUS

CN 1-Piperidinebutanamide, α-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 206553-76-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(5-chloro-2-methoxyphenyl)sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-77-7 CAPLUS
CN 1-Piperidinebutanamide, α-[[[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-78-8 CAPLUS
CN 1-Piperidinebutanamide, α-[[[([1,1'-biphenyl]-4-ylsulfonyl)methylamino]methyl]-N-hydroxy-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 206553-81-3 CAPLUS
CN 1-Piperidinebutanamide, N-hydroxy-α-[[methyl[(4-methylphenyl)sulfonyl]amino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 206553-91-5P 206553-96-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamides as metalloproteinase inhibitors)
RN 206553-91-5 CAPLUS
CN 1-Piperidinebutanoic acid, α-[3-[[(4-methoxyphenyl)sulfonyl]methylamino]propyl]-β-(2-methylpropyl)-γ-oxo-, 1,1-dimethylethyl ester, (αS,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206553-96-0 CAPLUS
CN 1-Piperidinebutanoic acid, α-[[[(4-methoxyphenyl)sulfonyl]methylamino]methyl]-β-(2-methylpropyl)-γ-oxo-, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
IT 203732-09-6P 203732-45-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylsulfonylaminohydroxamic acid derivs. as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))
RN 203732-09-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-45-0 CAPLUS
CN Benzenepropanamide, 4-chloro-N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]- (9CI) (CA INDEX NAME)



IT 203731-89-9P 203731-90-2P 203731-91-3P
203731-92-4P 203731-93-5P 203731-94-6P
203731-95-7P 203731-96-8P 203731-97-9P
203731-98-0P 203732-00-7P 203732-01-8P
203732-02-9P 203732-03-0P 203732-05-2P

203732-06-3P 203732-07-4P 203732-08-5P
203732-10-9P 203732-11-0P 203732-12-1P
203732-13-2P 203732-14-3P 203732-15-4P
203732-16-5P 203732-17-6P 203732-18-7P
203732-19-8P 203732-20-1P 203732-21-2P
203732-22-3P 203732-23-4P 203732-24-5P
203732-25-6P 203732-26-7P 203732-27-8P
203732-28-9P 203732-29-0P 203732-30-3P
203732-31-4P 203732-32-5P 203732-33-6P
203732-34-7P 203732-35-8P 203732-36-9P
203732-37-0P 203732-38-1P 203732-39-2P
203732-40-5P 203732-41-6P 203732-42-7P
203732-43-8P 203732-44-9P 203732-46-1P
203732-47-2P 203732-48-3P 203732-49-4P
203732-50-7P 203732-51-8P 203732-52-9P
203732-53-0P 203732-54-1P 203732-58-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfonylaminohydroxamic acid derivs. as inhibitors of matrix metalloproteinase and prodn. of tumor necrosis factor (TNF))

RN 203731-89-9 CAPLUS
CN Carbamic acid, [1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-90-2 CAPLUS
CN Butanamide, 2-[[3-[4-(acetyloxy)-1-piperidinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-91-3 CAPLUS
CN Butanoic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-92-4 CAPLUS
CN Butanamide, 2-[[3-[4-(benzoyloxy)-1-piperidinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-93-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-(4-hydroxy-1-piperidinyl)-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-94-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-95-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-96-8 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-97-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203731-98-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-00-7 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-01-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-02-9 CAPLUS
CN Cyclohexaneacetamide, N-hydroxy-α-[[3-(4-hydroxy-1-piperidinyl)-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 203732-06-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-07-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-08-5 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-03-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-05-2 CAPLUS
CN Carbamic acid, [1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 203732-10-9 CAPLUS
CN Carbamic acid, [1-[3-[[1-[[1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-11-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-12-1 CAPLUS
CN Carbamic acid, [1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-13-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-14-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 203732-17-6 CAPLUS
CN Pentanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-18-7 CAPLUS
CN Hexanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-19-8 CAPLUS
CN Pentanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-4,4-dimethyl-, monohydrochloride (9CI)



RN 203732-15-4 CAPLUS
CN Cyclohexaneacetamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-16-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-20-1 CAPLUS
CN Benzenepropanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-21-2 CAPLUS
CN Benzenepropanamide, 4-fluoro-N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-22-3 CAPLUS
CN Benzenebutanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-23-4 CAPLUS
CN Propanamide, 3-(1,1-dimethylethoxy)-N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-26-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-27-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



● HCl

RN 203732-24-5 CAPLUS
CN Cyclohexanepropanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-25-6 CAPLUS
CN 2-Naphthalenepropanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 203732-28-9 CAPLUS
CN 1-Piperazineacetic acid, 4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-29-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-30-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-31-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-32-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-33-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-37-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-38-1 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-34-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-35-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-36-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



● HCl

RN 203732-39-2 CAPLUS
CN Butanamide, 2-[[3-[4-(dimethylamino)-1-piperidinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-40-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-(3-hydroxypropyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-41-6 CAPLUS
CN Butanamide, 2-[[3-[1,4'-bipiperidin]-1'-yl-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 203732-42-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-phenoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-43-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-phenoxyphenyl)sulfonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 203732-44-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 203732-48-3 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)



RN 203732-49-4 CAPLUS
CN Butanamide, 2-[[3-[4-[2-(benzoyloxy)ethyl]-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-50-7 CAPLUS
CN Cyclohexaneacetamide, N-hydroxy-α-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 203732-51-8 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[5-(2-hydroxyethyl)-2,5-



RN 203732-46-1 CAPLUS
CN Cyclohexanepropanamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-[4-(methylamino)-1-piperidinyl]-3-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 203732-47-2 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-[4-(2-hydroxy-2-methylpropyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



diazabicyclo[2.2.1]hept-2-yl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-52-9 CAPLUS
CN Butanamide, N-hydroxy-2-[[3-(4-hydroxy-1-piperidinyl)-3-oxopropyl][(4-(phenylmethoxy)phenyl]sulfonyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-53-0 CAPLUS
CN Cyclohexaneacetamide, α-[[[4-(4-fluorophenoxy)phenyl]sulfonyl][3-(4-hydroxy-1-piperidinyl)-3-oxopropyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 203732-54-1 CAPLUS
CN Butanamide, 2-[[[4-(4-butylphenoxy)phenyl]sulfonyl][3-(4-hydroxy-1-

piperidinyl)-3-oxopropyl]amino]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 203732-58-5 CAPLUS
CN 2-Piperazinecarboxylic acid, 4-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 203732-80-3 203732-81-4 203732-82-5
203732-83-6 203732-84-7 203732-85-8
203732-86-9 203732-88-1 203732-89-2
203732-90-5 203732-91-6 203732-92-7
203732-93-8 203732-94-9 203732-95-0
203732-96-1 203732-97-2 203732-98-3
203732-99-4 203733-00-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylsulfonylaminohydroxamic acid derivs. as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))

RN 203732-80-3 CAPLUS
CN Carbamic acid, [1-[3-[[1-cyclohexyl-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-81-4 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-82-5 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-83-6 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-84-7 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-85-8 CAPLUS
CN Carbamic acid, [1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-86-9 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-88-1 CAPLUS
CN Carbamic acid, [1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-89-2 CAPLUS
CN Carbamic acid, [1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-90-5 CAPLUS
CN Carbamic acid, [1-[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 203732-91-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-92-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-methylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-93-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]pentyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-97-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3-phenylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-98-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(1,1-dimethylethoxy)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-99-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-(cyclohexylmethyl)-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-94-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(hydroxyamino)carbonyl]-3,3-dimethylbutyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-95-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-2-oxo-1-(phenylmethyl)ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203732-96-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[1-[(4-fluorophenyl)methyl]-2-(hydroxyamino)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203733-00-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[2-(hydroxyamino)-1-(2-naphthalenylmethyl)-2-oxoethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 203732-68-7P 203732-69-8P 203732-70-1P
203732-71-2P 203732-72-3P 203732-73-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylaminohydroxamic acid derivs. as inhibitors of matrix metalloproteinase and production of tumor necrosis factor (TNF))

RN 203732-68-7 CAPLUS
CN Cyclohexaneacetic acid, α-[[3-[4-[[(1,1-dimethylethoxy)carbonyl]methylamino]-1-piperidinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-69-8 CAPLUS
CN Cyclohexaneacetic acid, α-[[3-[4-[[(1,1-dimethylethoxy)carbonyl]methylamino]-1-piperidinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-70-1 CAPLUS
CN Carbamic acid, [1-[3-[[1-cyclohexyl-2-oxo-2-[(phenylmethoxy)amino]ethyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.





RN 203732-71-2 CAPLUS
CN D-Valine, N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl]-N-[(4-methoxyphenyl)sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203732-72-3 CAPLUS
CN D-Valine, N-[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl]-N-[(4-methoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 203732-73-4 CAPLUS
CN Butanamide, 2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]-3-oxopropyl][(4-methoxyphenyl)sulfonyl]amino]-3-methyl-N-(phenylmethoxy)-, (R)- (9CI) (CA INDEX NAME)

IT 182319-61-5P 182319-62-6P 182319-78-4P
182319-79-5P 182319-83-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (arylsulfonylamino)hydroxamates as matrix metalloproteinase
and tumor necrosis factor production inhibitors)

RN 182319-61-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl][(4-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-62-6 CAPLUS
CN Butanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperazinyl)propyl]amino]-3-methyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 182319-78-4 CAPLUS
CN Butanamide, N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-79-5 CAPLUS
CN Butanamide, N,3-dihydroxy-2-[[(4-methoxyphenyl)sulfonyl][3-oxo-3-(1-piperidinyl)propyl]amino]-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182319-83-1 CAPLUS
CN Cyclohexaneacetamide, N-hydroxy-α-[[(4-methoxyphenyl)sulfonyl][3-(4-methyl-1-piperazinyl)-3-oxopropyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 172738-38-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide derivs. as aspartyl protease inhibitors)
RN 172738-38-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-[[(1,1-dimethylethyl)amino]carbonyl]-4-[(3S)-3-hydroxy-4-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-oxobutyl]-, phenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 17:28:53 ON 09 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 17:29:02 ON 09 JUL 2007
L1               STRUCTURE UPLOADED
L2            29 S L1
L3           492 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 17:30:11 ON 09 JUL 2007
L4            15 S L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    85.16     257.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -11.70     -11.70

STN INTERNATIONAL LOGOFF AT 17:37:44 ON 09 JUL 2007


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16  CASREACT coverage extended
 NEWS  4  MAR 20  MARPAT now updated daily
 NEWS  5  MAR 22  LWPI reloaded
 NEWS  6  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01  New CAS web site launched
 NEWS 13  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS 15  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
```